Navigation Links
Perrigo's PBM Infant Formula Unit Wins Appellate Judgment Versus Mead Johnson
Date:4/21/2011

ALLEGAN, Mich., April 21, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that the United States Court of Appeals for the fourth Circuit has affirmed an earlier decision that Mead Johnson had engaged in false advertising resulting in an injunction prohibiting Mead Johnson from making similar claims and awarding damages in favor of PBM.

Perrigo's Chairman and CEO Joseph C. Papa concluded, "We are pleased that the Appeals Court affirmed the District Court's decision in favor of PBM. The Court has made it clear that national brand and store brand suppliers are entitled to fairly compete and advertising abuses will not be tolerated. We also appreciate the Court's recognition that PBM could lawfully compare its products to national brand products."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products.  The Company is the world's largest store brand manufacturer of OTC pharmaceutical products and infant formulas. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).  

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 26, 2010, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
2. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
3. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
4. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
5. Infant Formula Manufacturers Again under Ethical Cloud: Marketing Gimmick Linked to Serious Illnesses
6. Leukemia Therapy With Imatinib During Pregnancy May Cause Infant Abnormalities
7. Pregnant Women Need Omega-3 to Boost Infant Development
8. The COSHAR Foundation Launches National Childhood Immunization Awareness Campaign During National Infant Immunization Week (April 19-26)
9. Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
10. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
11. UPDATE: Infant Primates Given Vaccines on U.S. Childrens Immunization Schedule Develop Behavioral Symptoms of Autism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)...  Recently Zymo Research announced an exclusive license ... Horvath,s Clock. Based on this technology, Zymo Research ... academic and biopharma scientific researchers to determine the ... sperm. The service quantifies changes in ... chronological age following drug treatments and identifies disease ...
(Date:12/5/2016)... , Dec. 5, 2016  BD (Becton, Dickinson and ... medical technology company, will demonstrate an enhanced technology platform ... technologies, including the company,s leading Pyxis™ and Alaris™ systems, ... (ASHP) 2016 Midyear Meeting being held in ... While national data show that approximately 68 percent ...
(Date:12/5/2016)... 5, 2016 Research and Markets has announced ... Test Market Size, Share, Development, Growth and Demand Forecast to 2022" ... ... female fertility and pregnancy rapid test market is expected to grow ... and pregnancy rapid test market is witnessing high growth, due to ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... 2016 , ... For many years, Andrew G. Zubinas has accumulated ... beauty of the Lithuanian language and its poetry inspired him in writing ... lyrically explores all aspects of a living, breathing forest where nothing ever stays the ...
(Date:12/5/2016)... ... December 05, 2016 , ... T.E.N., ... that nominations will be accepted from December 5, 2016 through March 3, ... include the Information Security Executive® of the Year, which recognizes executives who ...
(Date:12/5/2016)... ... December 05, 2016 , ... Worldwise ®, a ... design firm kathy ireland® Worldwide for five additional years, announced by Kevin Fick, ... exclusive licensing agreement three years ago to design and develop the kathy ireland® ...
(Date:12/5/2016)... York, NY (PRWEB) , ... December 05, 2016 ... ... companies to use a patent-pending blend of L-Citrulline and glutathione to enhance production ... Blend, a combination that studies have shown to produce NO twice as effectively ...
(Date:12/5/2016)... Nashville, Tennessee (PRWEB) , ... ... ... leader in strategic interoperability, today announced that the company will provide alerting ... platform. CIHIE has been recently awarded $1.7 million in federal funds as ...
Breaking Medicine News(10 mins):